Company news

Alkermes plc news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Alkermes Investor Day to Focus on Scientific Progress and Value Creation Strategy

March 24, 2021

Alkermes Announces FDA Orphan Drug Designation for Nemvaleukin Alfa for Treatment of Mucosal Melanoma

March 10, 2021

Alkermes to Hold Virtual Investor Day

March 3, 2021

Alkermes to Take Part in SVB Leerink 10th Annual Global Healthcare Conference

February 17, 2021

Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2020 and Provides Financial Expectations for 2021

February 10, 2021

Alkermes to Host Conference Call to Discuss Fourth Quarter and Year-End 2020 Financial Results

February 3, 2021

NIDA-Funded Study Evaluating Extended-Release Injectable Naltrexone Plus Bupropion for the Treatment of Methamphetamine Use Disorder Published in New England Journal of Medicine

January 13, 2021

Alkermes to Present at the 39th Annual J.P. Morgan Healthcare Conference

January 5, 2021

FDA Accepts Alkermes' Resubmission of New Drug Application for ALKS 3831

December 28, 2020

Alkermes Announces Strategic Value Enhancement Plan and Continued Board Refreshment

December 9, 2020

Alkermes Receives FDA Complete Response Letter Related to ALKS 3831 Manufacturing Records Review

November 16, 2020

Alkermes Presents New Data on ALKS 4230 at Society for Immunotherapy of Cancer's (SITC) 35th Anniversary Annual Meeting

November 8, 2020

Alkermes Reschedules Third Quarter 2020 Financial Results Conference Call to 10: 30 a.m. ET

October 28, 2020

Alkermes to Host Conference Call to Discuss Third Quarter 2020 Financial Results

October 21, 2020

Alkermes Announces Posting of Briefing Documents for FDA Advisory Committee Meeting on ALKS 3831

October 6, 2020

Alkermes Presents New Psychiatry Data at Psych Congress 2020 Virtual Experience

September 13, 2020

Virtual FDA Advisory Committee Meeting to Review New Drug Application for ALKS 3831 for Treatment of Schizophrenia and Bipolar I Disorder Tentatively Scheduled for Oct. 9, 2020

August 20, 2020

Alkermes Initiates Phase 2 Study Designed to Evaluate Clinical and Immunologic Activity of ALKS 4230 on Tumor Microenvironment in Patients with Advanced Solid Tumors

August 18, 2020

Alkermes plc Reports Second Quarter 2020 Financial Results and Issues 2020 Financial Expectations

July 28, 2020

Alkermes to Host Conference Call to Discuss Second Quarter 2020 Financial Results

July 21, 2020

Alkermes Announces Launch of 3rd Annual Alkermes Pathways Research Awards® Program

June 28, 2020

Alkermes Awards COVID-19 Relief Fund Grants to 10 Innovative Programs Designed to Address Challenges for Patient Communities

June 23, 2020

Alkermes Announces Expansion of Patient Services and Provider Network to Support Uninterrupted Access to ARISTADA® and VIVITROL® During COVID-19 Crisis

May 10, 2020

Alkermes Launches COVID-19 Relief Fund to Support Innovative Programs Helping Vulnerable Patient Communities

May 3, 2020

Alkermes Plc Reports First Quarter 2020 Financial Results and Provides COVID-19 Related Business Update

April 28, 2020

Alkermes Announces Publication of Preclinical Data for ALKS 4230 in the Journal for ImmunoTherapy of Cancer

April 21, 2020

Alkermes Plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2019 and Provides Financial Expectations for 2020

February 12, 2020

Alkermes to Host Conference Call to Discuss Fourth Quarter and Year-End 2019 Financial Results

February 5, 2020

Alkermes Announces U.S. Food and Drug Administration Acceptance of ALKS 3831 New Drug Application for Treatment of Schizophrenia and Bipolar I Disorder

January 27, 2020

Alkermes Completes Acquisition of Rodin Therapeutics

November 24, 2019

Alkermes Submits New Drug Application to U.S. Food and Drug Administration for ALKS 3831 for Treatment of Schizophrenia and Bipolar I Disorder

November 18, 2019

Alkermes to Acquire Rodin Therapeutics

November 17, 2019

Alkermes Announces Receipt of $150 Million Milestone Payment from Biogen Related to FDA Approval of VUMERITY(TM)

November 11, 2019

Alkermes Announces New Data From ALKS 4230 Clinical Development Program at Society for Immunotherapy of Cancer's (SITC) 34th Annual Meeting

November 7, 2019

Alkermes to Present Data From ALKS 4230 Clinical Development Program at the Society for Immunotherapy of Cancer's (SITC) 34th Annual Meeting

November 3, 2019

Alkermes Plc Reports Third Quarter 2019 Financial Results and Implementation of Restructuring

October 22, 2019

Alkermes Announces Clinical Collaboration With Fred Hutchinson Cancer Research Center for Novel Immuno-Oncology Drug Candidate ALKS 4230

October 20, 2019

Alkermes to Host Conference Call to Discuss Third Quarter 2019 Financial Results

October 15, 2019

Alkermes Announces Settlement With Amneal Over VIVITROL® Patent Dispute

July 28, 2019

Alkermes Plc Reports Second Quarter 2019 Financial Results

July 24, 2019

Alkermes to Host Conference Call to Discuss Second Quarter 2019 Financial Results

July 17, 2019

Alkermes Expands Planned New Drug Application for ALKS 3831 to Include Treatment of Bipolar I Disorder

July 14, 2019

Alkermes Advances ALKS 4230 into Monotherapy Expansion Phase of ARTISTRY-1 in Patients With Renal Cell Carcinoma or Melanoma

June 11, 2019

Alkermes Plc Reports First Quarter 2019 Financial Results

April 24, 2019

Alkermes Appoints Industry Veteran C. Todd Nichols as Senior Vice President of Sales and Marketing

April 23, 2019

Alkermes to Host Conference Call to Discuss First Quarter 2019 Financial Results

April 17, 2019

Alkermes Announces Positive Topline Results From Innovative Study of ARISTADA® and INVEGA SUSTENNA® for the Treatment of Schizophrenia

April 8, 2019

Alkermes Announces Departure of Jim Robinson

April 7, 2019

Alkermes Expands Awards Program With Focus on Advancing Research in Schizophrenia

April 2, 2019

Alkermes to Present New ALKS 3831 Data From ENLIGHTEN-2 and Interim Extension Safety Study Results at 2019 Congress of the Schizophrenia International Research Society

March 31, 2019

← Newer news releases

Calls

The 5 newest of 24 calls. Every call is listed under its year.

Decks

The 5 newest of 73 decks. Every deck is listed under its year.